Low Frequency Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant Variants Contribute to Failure of Efavirenz‐Containing Regimens in Treatment‐Experienced Patients | Zendy

Elias K. Halvas | Zendy; Ann Wiegand | Zendy; Valerie F. Boltz | Zendy; Mary F. Kearney | Zendy; Dwight V. Nissley | Zendy; Michael Wantman | Zendy; Scott M. Hammer | Zendy; Sarah Palmer | Zendy; Florin Vaida | Zendy; John M. Coffin | Zendy; John W. Mellors | Zendy

Open Access

Low Frequency Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant Variants Contribute to Failure of Efavirenz‐Containing Regimens in Treatment‐Experienced Patients

Author(s) -

Elias K. Halvas,

Ann Wiegand,

Valerie F. Boltz,

Mary F. Kearney,

Dwight V. Nissley,

Michael Wantman,

Scott M. Hammer,

Sarah Palmer,

Florin Vaida,

John M. Coffin,

John W. Mellors

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/650542

Subject(s) - efavirenz , reverse transcriptase inhibitor , reverse transcriptase , virology , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , pharmacology , biology , viral load , polymerase chain reaction , genetics , gene

The contribution of low frequency drug-resistant human immunodeficiency virus type 1 (HIV-1) variants to failure of antiretroviral therapy is not well defined in treatment-experienced patients. We sought to detect minor nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants at the initiation of multidrug efavirenz-containing therapy in both NNRTI-naive and NNRTI-experienced patients and to determine their association with virologic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research